News | April 14, 2024
Briefs: Sun Pharma and Kimia Biosciences
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharma's Dadra facility receives OAI status from US FDA
The company will respond to the Warning Letter within the stipulated timelines
These observations are procedural in nature and will be responded within the stipulated time
_256_384.jpg)
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
The observations are procedural in nature and will be responded to within the stipulated time
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
A five-day inspection was concluded successfully with no critical and no major observations raised
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
ANVISA issues CGMP to Concord Biotech’s Unit I
Subscribe To Our Newsletter & Stay Updated
